Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
20 hedge funds and large institutions have $7.68M invested in Oncternal Therapeutics, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 4 closing their positions.
91% more capital invested
Capital invested by funds: $4.03M → $7.68M (+$3.65M)
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
13% less funds holding
Funds holding: 23 → 20 (-3)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$3.54M |
| 2 |
Renaissance Technologies
New York
|
+$115K |
| 3 |
BlackRock
New York
|
+$85.1K |
| 4 |
Morgan Stanley
New York
|
+$29.6K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.95K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$12K |
| 2 |
Millennium Management
New York
|
-$7.67K |
| 3 |
MAM
Meeder Asset Management
Dublin,
Ohio
|
-$6.49K |
| 4 |
State Street
Boston,
Massachusetts
|
-$5.3K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$959 |
ONCT Hedge Fund Activity: Q2 2020 in Review
20 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q2 2020, worth a combined $7.68M — up 91% from $4.03M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ONCT and 1 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 6 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $3.54M. The largest seller was Victory Capital Management, exiting entirely with an estimated $12K sold.
- 20 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q2 2020, down from 23 in Q1 2020.
- Funds reported $7.68M of Oncternal Therapeutics, Inc. Common Stock stock for Q2 2020, up 91% quarter-over-quarter.
- 1 fund opened new Oncternal Therapeutics, Inc. Common Stock positions in Q2 2020 and 4 closed out, a net change of -3 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q2 2020 was Armistice Capital, an estimated $3.54M added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q2 2020 was Victory Capital Management, an estimated $12K sold.
Based on aggregated 13F filings for Q2 2020.